What is bosutinib? What are its main ingredients and uses?

Bosutinib is a tyrosine kinase inhibitor used to treat certain types of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is a cancer of the blood system, mainly caused by rearrangement of the BCR-ABL1 gene, resulting in abnormal white blood cell proliferation. Bosutinib inhibits the activity of BCR-ABL1 tyrosine kinase and prevents the proliferation and spread of cancer cells, thereby effectively controlling the development of leukemia.

The main component of Bosutinib is Bosutinib (Bosutinib), which has highly selective and broad anti-cancer effects. Compared with other tyrosine kinase inhibitors (such as imatinib, dasatinib, nilotinib), bosutinib can effectively inhibit a variety of tyrosine kinases, including BCR-ABL1, and provides an effective alternative for patients with chronic myelogenous leukemia who are resistant to other treatments.

Bosutinib is used to treat chronic myelogenous leukemia, especially in patients who have failed or developed resistance to first-line treatments such as imatinib. It is often used as a second- or third-line treatment to help patients control disease progression, reduce symptoms, and prolong survival. Clinical studies have shown that bosutinib can significantly improve the complete molecular response rate (CMR) in patients with chronic myelogenous leukemia, that is, no measurable leukemia cells can be detected, which is crucial to improving the patient's quality of life.

Although bosutinib has a significant therapeutic effect on chronic myelogenous leukemia, it is also associated with certain side effects. Common adverse reactions include gastrointestinal symptoms (e.g., nausea, diarrhea, vomiting), liver function abnormalities, and thrombocytopenia. Therefore, patients need to undergo regular blood tests to monitor liver function and blood routine while receiving bosutinib treatment. Doctors usually adjust the dosage according to the patient's individual condition to reduce the occurrence of adverse reactions.

Reference materials:https://go.drugbank.com/drugs/DB06616